Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation

Information

  • Patent Grant
  • 7291144
  • Patent Number
    7,291,144
  • Date Filed
    Thursday, January 3, 2002
    22 years ago
  • Date Issued
    Tuesday, November 6, 2007
    17 years ago
Abstract
The present invention provides an enhanced method and device to inhibit or reduce the rate of restenosis following angioplasty or stent placement. The invention involves placing a balloon tipped catheter in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place from a balloon angioplasty. A fluid such as a perfluorocarbon may be flowed into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. The catheter may also be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon is in contact with at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium.
Description
CROSS-REFERENCE TO MICROFICHE APPENDIX

(none)


BACKGROUND OF THE INVENTION

Balloon angioplasty, or the technology of reshaping of a blood vessel for the purpose of establishing vessel patency using a balloon tipped catheter, has been known since the late 1970's. The procedure involves the use of a balloon catheter which is guided by means of a guidewire through a guiding catheter to the target lesion or vessel blockage. The balloon typically is equipped with one or more marker bands that allows the interventionalist to visualize the position of the balloon in reference to the lesion with the aid of fluoroscopy. Once in place, i.e., centered with the lesion, the balloon is inflated with a biocompatible fluid, and pressurized to the appropriate pressure to allow the vessel to open.


Typical procedures are completed with balloon inflation pressures between 8 and 12 atmospheres. A percentage of lesions, typically heavily calcified lesions, require much higher balloon inflation pressures, e.g., upward of 20 atmospheres. At times, the balloon inflation procedure is repeated several times before the lesion or blockage will yield. The placement of stents after angioplasty has become popular as it reduces the rate of restenosis.


Restenosis refers to the renarrowing of the vascular lumen following vascular intervention such as a balloon angioplasty procedure or stent insertion. Restenosis is clinically defined as a greater than 50% loss of initial lumen diameter. The mechanism or root causes of restenosis are still not fully understood. The causes are multifactorial, and are partly the result of the injury caused by the balloon angioplasty procedure and stent placement. With the advent of stents, restenosis rates have dropped from over 30% to 10-20%. Recently, the use and effectiveness of low-dose radiation administered intravascularly following angioplasty is being evaluated as a method to alter the DNA or RNA of an affected vessel's cells in the hope of reducing cell proliferation.


Besides restenosis, another cardiological malady is atrial fibrillation. Atrial fibrillation refers to very rapid irregular contractions of the atria of the heart resulting in a lack of synchronization between the heartbeat and the pulse. The irregular contractions are due to irregular electrical activity that originates in the area of the pulmonary veins. A proposed device, currently under development, for treating atrial fibrillation is a balloon filled with saline that can be ultrasonically agitated and heated. This device is inserted in the femoral vein and snaked into the right atrium. The device is then poked through the interatrial septum and into the left atrium, where it is then angled into the volume adjoining the suspect pulmonary vein with the left atrium.


Research in atrial fibrillation indicates that substantially complete circumferential necrosis is required for a therapeutic benefit. The above technique is disadvantageous in that circumferential portions of the tissue, desired to be necrosed, are not in fact affected. Other techniques, including RF ablation, are similarly inefficient. Moreover, these techniques leave the necrosed portions with jagged edges, i.e., there is poor demarcation between the healthy and the necrosed tissue. These edges can then cause electrical short circuits, and associated electrical irregularities, due to the high electric fields associated with jagged edges of a conductive medium.


The above technique is also disadvantageous in that heating is employed. Heating is associated with several problems, including increased coagulum and thrombus formation, leading to emboli. Heating also stimulates stenosis of the vein. Finally, since tissues can only safely be heated to temperatures of less than or about 75° C.-85° C. due to charring and tissue rupture secondary to steam formation. The thermal gradient thus induced is fairly minimal, leading to a limited heat transfer. Moreover, since heating causes tissues to become less adherent to the adjacent heat transfer element, the tissue contact with the heat transfer element is also reduced, further decreasing the heat transfer.


SUMMARY OF THE INVENTION

The present invention provides an enhanced method and device to inhibit or reduce the rate of restenosis following angioplasty or stent placement. The invention is similar to placing an ice pack on a sore or overstrained muscle for a period of time to minimize or inhibit the bio-chemical events responsible for an associated inflammatory response. An embodiment of the invention generally involves placing a balloon-tipped catheter in the area treated or opened through balloon angioplasty immediately following angioplasty. A so-called “cryoplasty” balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place from a balloon angioplasty. The dual balloon structure has benefits described below and also allows for a more robust design, providing significant safety advantages to the patient because two balloons must be broken if cooling fluid is to deleteriously infuse into the patient.


The dual balloon may be centered in the recently opened vessel with the aid of radio opaque marker bands, indicating the “working length” of the balloon. In choosing a working length, it is important to note that typical lesions may have a size on the order of 2-3 cm. A biocompatible heat transfer fluid, which may contain contrast media, may be infused through the space between the dual balloons. While this fluid does not circulate in this embodiment, once it is chilled or even frozen by thermal contact with a cooling fluid, it will stay sufficiently cold for therapeutic purposes. Subsequently, a biocompatible cooling fluid with a temperature between about, e.g., −40° C. and −60° C., may be injected into the interior of the inner balloon, and circulated through a supply lumen and a return lumen. The fluid exits the supply lumen through a skive in the lumen, and returns to the refrigeration unit via another skive and the return lumen.


The biocompatible cooling fluid chills the biocompatible heat transfer fluid between the dual balloons to a therapeutic temperature between about, e.g., 0° C. and −50° C. The chilled heat transfer fluid between the dual balloons transfers thermal energy through the balloon wall and into the adjacent intimal vascular tissue for the appropriate therapeutic length of time. Upon completion of the therapy, the circulation of the biocompatible cooling fluid is stopped, and the heat transfer fluid between the dual balloons withdrawn through the annular space. Both balloons may be collapsed by means of causing a soft vacuum in the lumens. Once collapsed, the cryoplasty catheter may be withdrawn from the treated site and patient through the guiding catheter.


In more detail, in one aspect, the invention is directed to a device to treat tissue, including an outer tube, an an inner tube disposed at least partially within the outer tube, and a dual balloon including an inner balloon and an outer balloon, the inner balloon coupled to the inner tube at a proximal and at a distal end, the outer balloon coupled to the inner tube at a distal end and to the outer tube at a proximal end. A first interior volume is defined between the outer balloon and the inner balloon in fluid communication with an inlet in the volume between the outer tube and the inner tube.


Variations of the invention may include one or more of the following. The inner tube may further define a guidewire lumen, a supply lumen, and return lumen. The supply lumen may define a hole or skive such that a fluid flowing in the supply lumen may be caused to flow into a volume defined by the inner balloon, and the return lumen may define a hole or skive such that a fluid flowing in a volume defined by the inner balloon may be caused to flow into the return lumen. The guidewire lumen may extend from a proximal end of the inner tube to a distal end of the inner tube. The device may further comprise at least two radially extending tabs disposed around a circumference of the inner tube to substantially center the inner tube within the dual balloon. The device may further comprise at least one marker band disposed on the inner tube to locate a working region of the device at a desired location. The device may further comprise a source of chilled fluid having a supply tube and a return tube, the supply tube coupled in fluid communication to the supply lumen and the return tube coupled in fluid communication to the return lumen. A source of fluid may also be included, the source of fluid coupled in fluid communication to a volume between the inner balloon and the outer balloon. The fluid may be a perfluorocarbon such as Galden fluid. The fluid may also include contrast media.


In another aspect, the invention is directed to a method of reducing restenosis after angioplasty in a blood vessel. The method includes inserting a catheter into a blood vessel, the catheter having a balloon. The balloon is then inflated with a perfluorocarbon such that an exterior surface of the balloon is in contact with at least a partial inner perimeter of the blood vessel, the perfluorocarbon having a temperature in the range of about −10° C. to −50° C.


Variations of the method may include one or more of the following. The method may include disposing the catheter at a desired location using at least one radio opaque marker band. The method may include flowing the perfluorocarbon into the balloon using a supply lumen and exhausting the perfluorocarbon from the balloon using a return lumen. The balloon may be a dual balloon, and the method may further include providing a heat transfer fluid in the volume between the dual balloons. The heat transfer fluid may include a contrast media fluid. The method may include disposing the catheter such that at least a portion of the balloon is in a coronary artery or in a carotid artery.


In yet another aspect, the invention is directed to a method of reducing atrial fibrillation. The method includes inserting a catheter at least partially into the heart, the catheter having a balloon, a portion of the balloon located in the left atrium and a portion of the balloon located in a pulmonary vein. The balloon is then inflated with a perfluorocarbon such that an exterior surface of the balloon is in contact with at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium, the perfluorocarbon having a temperature in the range of about −10° C. to −50° C.


Variations of the method may include one or more of the following. The balloon may have a working region having a length of between about 5 mm and 10 mm. The method may further include inserting a wire having a needle point from the femoral vein into the right atrium and forming a hole using the needle point in the interatrial septum between the right atrium and the left atrium. A guide catheter may then be inserted into the right atrium. A guide wire may further be inserted through the guide catheter into the right atrium and further into a pulmonary vein. The catheter may then be disposed over the guidewire into a volume defined by the joint of the right atrium and the pulmonary vein.


Advantages of the invention may include one or more of the following. The invention inhibits or reduces the rate of restenosis following a balloon angioplasty or any other type of vascular intervention. At least the following portions of the vascular anatomy can benefit from such a procedure: the abdominal aorta (following a stent or graft placement), the coronary arteries (following PTCA or rotational artherectomy), the carotid arteries (following an angioplasty or stent placement), as well as the larger peripheral arteries.


When the invention is used to treat atrial fibrillation, the following advantages inure. The cooled tissue is adherent to the heat transfer element, increasing the heat transfer effected. Since very cold temperatures may be employed, the temperature gradient can be quite large, increasing the heat transfer rate.


In both embodiments, heat transfer does not occur primarily or at all by vaporization of a liquid, thus eliminating a potential cause of bubbles in the body. Nor does cooling occur primarily or at all by a pressure change across a restriction or orifice, this simplifying the structure of the device. Thrombus formation and charring, associated with prior techniques, are minimized or eliminated.


Additional advantages will be apparent from the description that follows, including the drawings and claims.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A shows a side schematic view of a catheter according to a first embodiment of the invention.



FIG. 1B shows a cross-sectional view of the catheter of FIG. 1A, as indicated by lines 1B-1B in FIG. 1A.



FIG. 2A shows a side schematic view of a catheter according to a second embodiment of the invention.



FIG. 2B shows a cross-sectional view of the catheter of FIG. 2A, as indicated by lines 2B-2B in FIG. 2A.





DETAILED DESCRIPTION

Referring to FIG. 1A, a catheter 100 is shown according to a first embodiment of the invention. The catheter 100 has a proximal end 130 and a distal end 114. Of course, this figure is not necessarily to scale and in general use the proximal end 130 is far upstream of the features shown in FIG. 1A.


The catheter 100 may be used within a guide catheter 102, and generally includes an outer tube 103, a dual balloon 134, and an inner tube 122. These parts will be discussed in turn.


The guide catheter 102 provides a tool to dispose the catheter 100 adjacent the desired location for, e.g., angioplasty or reduction of atrial fibrillation. Typical guide catheter diameters may be about 6 french to 9 french, and the same may be made of polyether blockamide, polyamides, polyurethanes, and other similar materials. The distal end of the guide catheter is generally adjacent the proximal end of the dual balloon 134, and further is generally adjacent the distal end of the outer tube 103.


The ability to place the guide catheter is a significant factor in the size of the device. For example, to perform angioplasty in the carotid arteries, which have an inner diameter of about 4 to 6 mm, a suitably sized guide catheter must be used. This restricts the size of the catheter 100 that may be disposed within the guide catheter. A typical diameter of the catheter 100 may then be about 7 french or less or about 65 to 91 mils. In a second embodiment described below, a catheter for use in the coronary arteries is described. Of course, which catheter is used in which artery is a matter to be determined by the physician, taking into account such factors as the size of the individual patient's affected arteries, etc.


The outer tube 103 houses the catheter 100 while the latter traverses the length of the guide catheter 102. The outer tube 103 may have a diameter of about 4 french to 7 french, and the same may be made of polyether blockamide, poly-butylene terephtalate, polyurethane, polyamide, polyacetal polysulfone, polyethylene, ethylene tetrafluoroethylene, and other similar materials.


The distal end of the outer tube 103 adjoins the proximal end of the dual balloon 134. The outer tube 103 provides a convenient location for mounting a proximal end of an outer balloon 104 within the dual balloon 134, and further may provide an inlet 128 for providing a fluid such as a liquid to a first interior volume 106 between the dual balloons. In some cases, an inlet 128 per se may not be necessary: the fluid, which may also be a sub-atmospheric level of gas or air, may be provided during manufacture in the first interior volume 106. In this case, the proximal and distal ends of the first interior volume may be sealed during manufacture. The inlet 128 may be at least partially defined by the annular volume between the interior of the outer tube 103 and the exterior of the inner tube 122.


The dual balloon 134 includes an outer balloon 104 and an inner balloon 108. Between the two is the first interior volume 106. The outer balloon 104 may be inflated by inflating the interior volume 106. The inner balloon 108 has a second interior volume 110 associated with the same. The inner balloon 108 may be inflated by inflating the second interior volume 110.


To avoid the occurrence of bubbles in the bloodstream, both the inner balloon 108 and the outer balloon 104 may be inflated using biocompatible liquids, such as Galden® fluid, perfluorocarbon-based liquids, or various contrast agents. There is no need that the fluid inflating one of the interior volumes be the same fluid as that inflating the other. Additional details on these fluids are described below.


In the case of the first interior volume 106, this fluid may be, e.g., stationary or static: in other words, it need not be circulated. In the case of the second interior volume 110, this fluid would in general be circulated by an external chiller (not shown). The chiller may be, e.g., a gear pump, peristaltic pump, etc. It may be preferable to use a gear pump over a peristaltic pump as the attainable pressure of the former is generally greater than that of the latter. Moreover, gear pumps have the advantageous property of being linear, i.e., their output varies in direction proportion with their revolutions per minute. Two types of gear pumps which may be employed include radial spur gear pumps and helical tooth gear pumps. Of these, the helical tooth gear pump may be more preferable as the same has been associated with higher pressures and a more constant output. The ability to achieve high pressures may be important as the cooling fluid is required to pass through a fairly narrow, e.g., five to seven french, catheter at a certain rate. For the same reason, the viscosity of the fluid, at the low temperatures, should be appropriately low. For example, an appropriate type of fluid may be Galden® fluid, and in particular Galden® fluid item number “HT-55”, available from Ausimont Inc. of Thorofare, N.J. At −55° C., this fluid has a viscosity of 2.1 centiStokes. At −70° C., this fluid has a viscosity of 3.8 centiStokes. It is believed that fluids with such viscosities at these temperatures would be appropriate for use.


The so-called “cones” of the balloons 108 and 104, indicated generally by reference numeral 132, may be made somewhat thicker than the remainder of the balloon sections. In this way, the heat transfer efficiency in these sections is significantly less than over the remainder of the balloon sections, this “remainder” effectively defining a “working region” of the balloon. In this way, the cooling or “cryoplasty” may be efficiently localized to the affected area rather than spread over the length of the balloon.


The inner tube 122 is disposed within the interior of the dual balloon 134 and within the interior of the guide catheter 102. The inner tube 122 includes a supply lumen 120, a return lumen 118, and a guidewire lumen 116. The guidewire lumen 116 may have sizes of, e.g., 17 or 21 mils inner diameter, in order to accommodate current standard sized guidewires, such as those having an outer diameter of 14 mils. This structure may be preferable to a coaxial structure, as the pressure drop encountered may be substantially less. In use, the supply lumen 120 may be used to supply a circulating liquid to the second interior volume 110. The return lumen 118 may be used to exhaust the circulating liquid from the second interior volume to the external chiller. As may be seen from FIG. 1A, both lumens 118 and 120 may terminate prior to the distal end 114 of the catheter 100. The lumen arrangement may be seen more clearly in FIG. 1B.


A set of radio opaque marker bands 112 may be disposed on the inner tube 122 at locations substantially adjacent the cones 132 to define a central portion of the “working region” of the balloons 104 and 108. This working region is where the “cryoplasty” procedures described below may substantially occur.


As noted above, the proximal portion of the outer balloon 104 is mounted on the outer tube 103 at its distal end. The distal end of the outer balloon 104 is secured to the distal end of the catheter 100 and along the inner tube 122. In contrast, both the proximal and distal ends of the inner balloon 108 may be secured to the inner tube 122 to create a sealed second interior volume 110.


At least two skives 124 and 126 may be defined by the inner tube 122 and employed to allow the working fluid to exit into the second interior volume 110 and to exhaust the same from the second interior volume 10. As shown in the figure, the skive 124 is in fluid communication with the lumen 120 and the skive 126 is in fluid communication with the lumen 118. Here, “fluid communication” refers to a relationship between two vessels where a fluid pressure may cause a net amount of fluid to flow from one vessel to the other.


The skives may be formed by known techniques. A suitable size for the skives may be from about 50 mils to 125 mils.


A plurality of tabs 119 may be employed to roughly or substantially center the inner tube 122 within the catheter 100. These tabs may have the shape shown, the shape of rectangular or triangular solids, or other such shapes so long as the flow of working fluid is not unduly impeded. In this specification, the phrase “the flow of working fluid is not unduly impeded” is essentially equated to the phrase “substantially center”. The tabs 119 may be made of polyether blockamide, poly-butylene terephtalate, polyurethane, polyamide, polyacetal polysulfone, polyethylene, ethylene tetrafluoroethylene, and other similar materials, and may have general dimensions of from about 3 mils to 10 mils in height, and by about 10 mils to 20 mils in width.


In a method of use, the guide catheter 102 may be inserted into an affected artery or vein such that the distal tip of the guide catheter is just proximal to an affected area such as a calcified area or lesion. Of course, it is noted that typical lesions do not occur in the venous system, but only in the arterial.


This step provides a coarse estimate of proper positioning, and may include the use of fluoroscopy. The guide catheter may be placed using a guide wire (not shown). Both the guide catheter and guide wire may already be in place as it may be presumed a balloon angioplasty or stent placement has previously been performed.


The catheter 100 may then be inserted over the guide wire via the lumen 116 and through the guide catheter 102. In general, both a guide wire and a guide catheter are not strictly necessary—one or the other may often suffice. During insertion, the dual balloon 134 may be uninflated to maintain a minimum profile. In fact, a slight vacuum may be drawn to further decrease the size of the dual balloon 134 so long as the structural integrity of the dual balloon 134 is not thereby compromised.


When the catheter 100 is distal of the distal tip of the guide catheter 102, a fine positioning step may occur by way of the radio opaque marker bands 112. Using fluoroscopy, the location of the radio opaque marker bands 112 can be identified in relation to the location of the lesion. In particular, the catheter may be advantageously placed at the location of the lesion and further such that the lesion is between the two marker bands. In this way, the working region of the balloon 134 will substantially overlap the affected area, i.e., the area of the lesion.


Once placed, a biocompatible heat transfer fluid, which may also contain contrast media, may be infused into the first interior volume 106 through the inlet 128. While the use of contrast media is not required, its use may allow early detection of a break in the balloon 104 because the contrast media may be seen via fluoroscopy to flow throughout the patient's vasculature. Subsequently a biocompatible cooling fluid may be circulated through the supply lumen 120 and the return lumen 118. Before or during the procedure, the temperature of the biocompatible cooling fluid may be lowered to a therapeutic temperature, e.g., between −40° C. and −60° C., although the exact temperature required depends on the nature of the affected area. The fluid exits the supply lumen 120 through the skive 124 and returns to the chiller through the skive 126 and via the return lumen 118. It is understood that the respective skive functions may also be reversed without departing from the scope of the invention.


The biocompatible cooling fluid in the second interior volume 110 chills the biocompatible heat transfer fluid within the first interior volume 106 to a therapeutic temperature of, e.g., between about −25° C. and −50° C. The chilled heat transfer fluid transfers thermal energy through the wall of the balloon 104 and into the adjacent intimal vascular tissue for an appropriate therapeutic length of time. This time may be, e.g., about 12 to 4 minutes.


Upon completion of the therapy, the circulation of the biocompatible cooling fluid may cease. The heat transfer fluid within the first interior volume 106 may be withdrawn though the inlet 128. The balloons 104 and 108 may be collapsed by pulling a soft vacuum through any or all of the lumens 124, 126, and 128. Following collapse, the catheter 100 may be withdrawn from the treatment site and from the patient through the guide catheter 102.


To inhibit restenosis, the following therapeutic guidelines may be suggested:

















Minimum
Average
Maximum



















Temperature of heat
−20° C.
−55° C.
−110° C.


transfer fluid


Temperature
0° C. to −10° C.
−20° C. to
−50° C. to


achieved at intimal

−30° C.
−100° C.


wall


Depth of penetration
10ths of mm
1 mm
3 mm


of intema/media


Length of time fluid
30 seconds
1-2 min
4-5 min


is circulating









Substantially the same catheter may be used to treat atrial fibrillation. In this method, the catheter is inflated as above once it is in location. The location chosen for treatment of atrial fibrillation is such that the working region spans a portion of the left atrium and a portion of the affected pulmonary vein. Thus, in this embodiment, the working region of the catheter may have a length of about 5 mm to 30 mm. The affected pulmonary vein, of the four possible pulmonary veins, which enter the left atrium, may be determined by electrophysiology studies.


To maneuver the catheter into this location, a catheter with a needle point may first be inserted at the femoral vein and routed up to the right atrium. The needle of the catheter may then be poked through the interatrial septum and into the left atrium. The catheter may then be removed if desired and a guide catheter disposed in the same location. A guide wire may be used through the guide catheter and may be maneuvered at least partially into the pulmonary vein. Finally, a catheter such as the catheter 100 may be placed in the volume defining the intersection of the pulmonary vein and the left atrium.


A method of use similar to that disclosed above is then employed to cool at least a portion of, and preferably all of, the circumferential tissue. The coldness of the balloon assists in the adherence of the circumferential tissue to the balloon, this feature serving to increase the overall heat transfer rate.


The catheter 100 above may be particularly useful for procedures in the carotid arteries by virtue of its size. For use in the coronary arteries, which are typically much smaller than the carotid artery, an even smaller catheter may be desired.


Referring to FIG. 2A, a catheter 200 is shown according to a second embodiment of the invention. This embodiment may be particularly useful for use in the coronary arteries because the dimensions of the catheter 200 may be considerably smaller than the dimensions of the catheter 100. However, in several ways the catheter 200 is similar to the above-described catheter 100. In particular, the catheter 200 has a proximal end 230 and a distal end 214 and may be used within a guide catheter 202. The catheter 200 includes an outer tube 203, a dual balloon 234, and an inner tube 222.


The ability to place the guide catheter is a significant factor in the size of the device. For example, to perform angioplasty in the coronary arteries, which have an inner diameter of about 1½ to 4½ mm, a suitably sized guide catheter may be used. This then restricts the size of the catheter 200 which may be disposed within the guide catheter. A typical diameter of the catheter 200 may then be about 3 french or less or about 35-39 mils. The same may be placed in the femoral artery in order to be able to track to the coronary arteries in a known manner.


Analogous to these features in the catheter 100, the outer tube 203 houses the catheter 200 and may have an outside diameter of about 5 french to 7 french, and the same may be made of similar materials. The distal end of the outer tube 203 adjoins the proximal end of the dual balloon 234. The outer tube 203 provides a mounting location for an outer balloon 204, and further provides an inlet 228 for providing a fluid such as a liquid to a first interior volume 206 between the dual balloons. As noted in connection with catheter 100, an inlet 228 per se may not be necessary: the fluid, which may also be a sub-atmospheric level of air, may be provided in the first interior volume 206. Also as above, the proximal and distal ends of the volume may be sealed during manufacture. The inlet 228 may be at least partially defined by the annular volume between the interior of the outer tube 203 and the exterior of the inner tube 222.


The dual balloon 234 includes an outer balloon 204 and an inner balloon 208. These balloons are basically similar to balloons 104 and 108 described above, but may be made even smaller for use in the smaller coronary arteries.


The same types of fluids may be used as in the catheter 100.


The inner tube 222 is disposed within the interior of the dual balloon 234 and within the interior of the guide catheter 202. The inner tube 222 includes a supply lumen 220 and a return lumen 218.


A set of radio opaque marker bands 212 may be disposed on the inner tube 222 for the same reasons disclosed above in connection with the marker bands 112.


As noted above, the proximal portion of the outer balloon 204 is mounted on the outer tube 203 at its distal end. The distal end of the outer balloon 204 is secured to the distal end of the catheter 200 and along the inner tube 222. In contrast, both the proximal and distal ends of the inner balloon 208 may be secured to the inner tube 222 to create a sealed second interior volume 210.


At least two skives 224 and 226 may be defined by the inner tube 222 and employed to allow the working fluid to exit into the second interior volume 210 and to exhaust the same from the second interior volume 210.


A plurality of tabs 219 may be employed to roughly or substantially center the inner tube 222 within the catheter 200 as in catheter 100. These tabs may have the same general geometry and design as tabs 119. Of course, they may also be appropriately smaller to accommodate the smaller dimensions of this coronary artery design.


The tabs 119 and 219 are particularly important in the catheters 100 and 200, respectively, because the tabs lessen the pressure drop encountered by the fluid. Contact by the inner tube of the outer tube may also be associated with an undesired heat transfer prior to the working fluid reaching the working region, thereby deleteriously increasing the temperature of the working fluid at the working region.


The method of use of the catheter 200 is generally the same as for the catheter 100. Known techniques may be employed to place the catheter 200 into an affected coronary artery. For the catheter 200, an external guidewire may be used with appropriate attachments to the catheter.


The invention has been described above with respect to particular embodiments. It will be clear to one of skill in the art that numerous variations may be made from the above embodiments with departing from the spirit and scope of the invention. For example, the invention may be combined with stent therapies or other such procedures. The dual balloon disclosed may be used after angioplasty or may be an angioplasty balloon itself. Furthermore, while the invention has occasionally been termed herein a “cryoplasty catheter”, such a term is for identification purposes only and should not be viewed as limiting of the invention. Fluids that may be used as heat transfer fluids include perfluorocarbon-based liquids, i.e., halogenated hydrocarbons with an ether bond, such as FC 72. Other materials that may be used include CFCs, Freon®, or chemicals that when placed together cause an endothermic reaction. Preferably, low viscosity materials are used as these result generally in a lessened pressure drop. The balloons may be made, e.g., of Pebax, PET/PEN, PE, PA 11/12, PU, or other such materials. Either or both of the dual balloons may be doped to improve their thermal conductivities. The shaft of inner tube 122 may be made of Pebax, PBT, PI/PEI, PU, PA 11/12, SI, or other such materials. Other variations will be clear to one of skill in the art, thus the invention is limited only by the claims appended hereto.

Claims
  • 1. A method of reducing atrial fibrillation, comprising: inserting a catheter at least partially into the heart, the catheter having a dual balloon structure, including an outer balloon and an inner balloon contained within the outer balloon, a portion of the dual balloon structure located in the left atrium and a portion of the dual balloon structure located in a pulmonary vein; andinflating at least the outer balloon with a perfluorocarbon such that an exterior surface of the outer balloon is in contact with at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium, the perfluorocarbon having a temperature in the range of about −10° C. to −50° C.
  • 2. The method of claim 1, wherein the dual balloon structure has a working region having a length of between about 5 mm and 10 mm.
  • 3. The method of claim 1, further comprising: inserting a wire capable of rupturing the atrial septum from the femoral vein into the right atrium;funning a hole using the wire in the interatrial septum between the right atrium and the left atrium;inserting a guide catheter into the right atrium;inserting a guide wire through the guide catheter into the right atrium and further into a pulmonary vein;disposing the catheter aver the guidewire into a volume defined by the joint of the right atrium and the pulmonary vein.
  • 4. The method of claim 1, further comprising inflating the inner balloon with a biocompatible liquid.
  • 5. The method of claim 4, wherein the biocompatible liquid is static.
  • 6. The method of claim 4, wherein the biocompatible liquid contains contrast media.
  • 7. The method of claim 5, wherein the biocompatible liquid in the inner balloon chills biocompatible fluid between the dual balloons.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 09/516,319, filed Mar. 1, 2000 now abandoned, entitled “Method and Device for Performing Cooling- or Cryo-Therapies for, e.g., Angioplasty with Reduced Restenosis or Pulmonary Vein Cell Necrosis to Inhibit Atrial Fibrillation”, which is a continuation-in-part of U.S. patent application Ser. No. 09/052,545, filed Mar. 31, 1998, entitled “Circulating Fluid Hypothermia Method and Apparatus”, now U.S. Pat. No. 6,231,595 and U.S. patent application Ser. No. 09/215,038, filed Dec. 16, 1998, entitled “Inflatable Catheter for Selective Organ Heating and Cooling and Method of Using the Same”, now U.S. Pat. No. 6,261,312.

US Referenced Citations (346)
Number Name Date Kind
2308484 Auzin et al. Jan 1943 A
2374609 McCollum Apr 1945 A
2615686 Davidson Oct 1952 A
2672032 Towse Mar 1954 A
2913009 Kuthe Nov 1959 A
3125096 Antiles et al. Mar 1964 A
3228400 Armao Jan 1966 A
3298371 Lee Jan 1967 A
3369549 Armao Feb 1968 A
3425419 Dato Feb 1969 A
3504674 Swenson et al. Apr 1970 A
3604419 Diskin et al. Sep 1971 A
3612175 Ford et al. Oct 1971 A
3674031 Weiche Jul 1972 A
3696813 Wallach Oct 1972 A
3786814 Armao Jan 1974 A
3859986 Okada et al. Jan 1975 A
3865116 Brooks Feb 1975 A
3867294 Pall et al. Feb 1975 A
3888259 Miley Jun 1975 A
3889680 Armao Jun 1975 A
3971383 Van Gerven Jul 1976 A
4038519 Foucras Jul 1977 A
4153048 Magrini May 1979 A
4160455 Law Jul 1979 A
4190033 Foti Feb 1980 A
4231425 Engstrom Nov 1980 A
4275734 Mitchiner Jun 1981 A
4298006 Parks Nov 1981 A
4318722 Altman Mar 1982 A
4323071 Simpson et al. Apr 1982 A
4427009 Wells et al. Jan 1984 A
4445500 Osterholm May 1984 A
4464172 Lichtenstein Aug 1984 A
4483341 Witteles Nov 1984 A
4502286 Okada et al. Mar 1985 A
4569355 Bitterly Feb 1986 A
4581017 Sahota Apr 1986 A
4602642 O'Hara Jul 1986 A
4655746 Daniels et al. Apr 1987 A
4672962 Hershenson Jun 1987 A
4745922 Taylor May 1988 A
4747826 Sassano May 1988 A
4748979 Hershenson Jun 1988 A
4750493 Brader Jun 1988 A
4762129 Bonzel Aug 1988 A
4762130 Fogarty et al. Aug 1988 A
4781033 Steyert Nov 1988 A
4781799 Herbert, Jr. et al. Nov 1988 A
4820349 Saab Apr 1989 A
4860744 Johnson et al. Aug 1989 A
4883455 Leonard Nov 1989 A
4894164 Polaschegg Jan 1990 A
4904237 Janese Feb 1990 A
4920963 Brader May 1990 A
4951677 Crowley et al. Aug 1990 A
4964409 Tremulis Oct 1990 A
5000734 Boussignac et al. Mar 1991 A
5002531 Bonzel Mar 1991 A
5014695 Benak et al. May 1991 A
5018521 Campbell May 1991 A
5019075 Spears et al. May 1991 A
5024668 Peters et al. Jun 1991 A
5041089 Mueller et al. Aug 1991 A
5046497 Millar Sep 1991 A
5078713 Varney Jan 1992 A
5089260 Hunter et al. Feb 1992 A
5092841 Spears Mar 1992 A
5106360 Ishwara et al. Apr 1992 A
5106368 Uldall et al. Apr 1992 A
5108390 Potocky et al. Apr 1992 A
RE33911 Samson et al. May 1992 E
5110721 Anaise et al. May 1992 A
5112438 Bowers May 1992 A
5117822 Laghi Jun 1992 A
5147355 Friedman et al. Sep 1992 A
5149321 Klatz et al. Sep 1992 A
5150706 Cox et al. Sep 1992 A
5151100 Abele et al. Sep 1992 A
5180364 Ginsburg Jan 1993 A
5190539 Fletcher et al. Mar 1993 A
5191883 Lennox et al. Mar 1993 A
5196024 Barath Mar 1993 A
5211631 Sheaff May 1993 A
5234405 Klatz et al. Aug 1993 A
5236908 Gruber et al. Aug 1993 A
5246421 Saab Sep 1993 A
5248312 Langberg Sep 1993 A
5250070 Parodi Oct 1993 A
5257977 Eshel Nov 1993 A
5264260 Saab Nov 1993 A
5267341 Shearin Nov 1993 A
5269369 Faghri Dec 1993 A
5269749 Koturov Dec 1993 A
5269758 Taheri Dec 1993 A
5281213 Milder et al. Jan 1994 A
5281215 Milder Jan 1994 A
5306261 Alliger et al. Apr 1994 A
5310440 Zingher May 1994 A
5334193 Nardella Aug 1994 A
5337734 Saab Aug 1994 A
5342301 Saab Aug 1994 A
5344436 Fontenot et al. Sep 1994 A
5358486 Saab Oct 1994 A
5365750 Greenthal Nov 1994 A
5368591 Lennox et al. Nov 1994 A
5383854 Safar et al. Jan 1995 A
5383918 Panetta Jan 1995 A
5385148 Lesh et al. Jan 1995 A
5395314 Klatz et al. Mar 1995 A
5395331 O'Neill et al. Mar 1995 A
5403281 O'Neill et al. Apr 1995 A
5411477 Saab May 1995 A
5417686 Peterson et al. May 1995 A
5423745 Todd et al. Jun 1995 A
5423807 Milder Jun 1995 A
5433740 Yamaguchi Jul 1995 A
5437673 Baust et al. Aug 1995 A
5443456 Alliger et al. Aug 1995 A
5443781 Saab Aug 1995 A
5462521 Brucker et al. Oct 1995 A
5486204 Clifton Jan 1996 A
5486208 Ginsburg Jan 1996 A
5496271 Burton et al. Mar 1996 A
5499973 Saab Mar 1996 A
5520682 Baust et al. May 1996 A
5531776 Ward et al. Jul 1996 A
5536247 Thornton Jul 1996 A
5549559 Eshel Aug 1996 A
5554119 Harrison et al. Sep 1996 A
5558644 Boyd et al. Sep 1996 A
5569195 Saab Oct 1996 A
5573532 Chang et al. Nov 1996 A
5578008 Hara Nov 1996 A
5584804 Klatz et al. Dec 1996 A
5588438 McKown et al. Dec 1996 A
5591162 Fletcher et al. Jan 1997 A
5620480 Rudie Apr 1997 A
5622182 Jaffe Apr 1997 A
5624392 Saab Apr 1997 A
5630837 Crowley May 1997 A
5643197 Brucker et al. Jul 1997 A
5647051 Neer Jul 1997 A
5653692 Masterson et al. Aug 1997 A
5676693 LaFontaine Oct 1997 A
5709654 Klatz et al. Jan 1998 A
5713941 Robins et al. Feb 1998 A
5716386 Ward et al. Feb 1998 A
5733280 Avitall Mar 1998 A
5733318 Augustine Mar 1998 A
5733319 Neilson et al. Mar 1998 A
5735809 Gorsuch Apr 1998 A
5741248 Stern et al. Apr 1998 A
5755690 Saab May 1998 A
5792140 Tu et al. Aug 1998 A
5797878 Bleam Aug 1998 A
5799661 Boyd et al. Sep 1998 A
5800480 Augustine et al. Sep 1998 A
5800483 Vought Sep 1998 A
5800488 Crockett Sep 1998 A
5800516 Fine et al. Sep 1998 A
5807391 Wijkamp Sep 1998 A
5820593 Safar et al. Oct 1998 A
5824030 Yang et al. Oct 1998 A
5827222 Klatz et al. Oct 1998 A
5827237 Macoviak et al. Oct 1998 A
5827269 Saadat Oct 1998 A
5833671 Macoviak et al. Nov 1998 A
5833673 Ockuly et al. Nov 1998 A
5834465 Olney Nov 1998 A
5837003 Ginsburg Nov 1998 A
5861021 Thome Jan 1999 A
5868735 Lafonatine Feb 1999 A
5871526 Gibbs et al. Feb 1999 A
5873835 Hastings et al. Feb 1999 A
5879316 Safar et al. Mar 1999 A
5879329 Ginsburg Mar 1999 A
5899898 Arless et al. May 1999 A
5899899 Arless et al. May 1999 A
5901783 Dobak, III et al. May 1999 A
5902268 Saab May 1999 A
5906588 Safar et al. May 1999 A
5906594 Scarfone et al. May 1999 A
5906636 Casscells, III et al. May 1999 A
5913856 Chia et al. Jun 1999 A
5913885 Klatz et al. Jun 1999 A
5913886 Soloman Jun 1999 A
5916242 Schwartz Jun 1999 A
5921982 Lesh et al. Jul 1999 A
5938660 Swartz et al. Aug 1999 A
5957917 Doiron et al. Sep 1999 A
5957963 Dobak, III Sep 1999 A
5964751 Amplatz et al. Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5968009 Simán Oct 1999 A
5971979 Joye et al. Oct 1999 A
5971983 Lesh Oct 1999 A
5989238 Ginsburg Nov 1999 A
6004289 Saab Dec 1999 A
6007692 Herbert et al. Dec 1999 A
6011995 Guglielmi et al. Jan 2000 A
6012457 Lesh Jan 2000 A
6019783 Philips et al. Feb 2000 A
6022336 Zadno-Azizi et al. Feb 2000 A
6024740 Lesh et al. Feb 2000 A
6033383 Ginsburg Mar 2000 A
6042559 Dobak, III Mar 2000 A
6051019 Dobak, III Apr 2000 A
6063101 Jacobsen et al. May 2000 A
6096068 Dobak, III et al. Aug 2000 A
6106518 Wittenberger et al. Aug 2000 A
6110168 Ginsburg Aug 2000 A
6117101 Diederich et al. Sep 2000 A
6126684 Gobin et al. Oct 2000 A
6146411 Noda et al. Nov 2000 A
6146814 Millet Nov 2000 A
6149670 Worthen et al. Nov 2000 A
6149673 Ginsburg Nov 2000 A
6149676 Ginsburg Nov 2000 A
6149677 Dobak, III Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6164283 Lesh Dec 2000 A
6165207 Balding et al. Dec 2000 A
6168594 Lafontaine et al. Jan 2001 B1
6182666 Dobak, III Feb 2001 B1
6193644 Dobak, III et al. Feb 2001 B1
6206004 Schmidt et al. Mar 2001 B1
6213126 Lafontaine et al. Apr 2001 B1
6217528 Koblish et al. Apr 2001 B1
6224624 Lasheras et al. May 2001 B1
6231561 Frazier et al. May 2001 B1
6231594 Dae May 2001 B1
6231595 Dobak, III May 2001 B1
6235018 Lepivert May 2001 B1
6235019 Lehmann et al. May 2001 B1
6235048 Dobak, III May 2001 B1
6238428 Werneth et al. May 2001 B1
6241718 Arless et al. Jun 2001 B1
6241722 Dobak et al. Jun 2001 B1
6245064 Lesh et al. Jun 2001 B1
6245095 Dobak, III et al. Jun 2001 B1
6248057 Mavity et al. Jun 2001 B1
6251093 Valley et al. Jun 2001 B1
6251129 Dobak, III et al. Jun 2001 B1
6251130 Dobak, III et al. Jun 2001 B1
6253769 LaFontaine et al. Jul 2001 B1
6254588 Jones et al. Jul 2001 B1
6254626 Dobak, III et al. Jul 2001 B1
6261312 Dobak, III et al. Jul 2001 B1
6264679 Keller et al. Jul 2001 B1
6267747 Samson et al. Jul 2001 B1
6270476 Santoianni et al. Aug 2001 B1
6270493 Lalonde et al. Aug 2001 B1
6270494 Kovalcheck et al. Aug 2001 B1
6287326 Pecor Sep 2001 B1
6290674 Roue et al. Sep 2001 B1
6290696 LaFontaine Sep 2001 B1
6290697 Tu et al. Sep 2001 B1
6290717 Phillips Sep 2001 B1
6295990 Lewis et al. Oct 2001 B1
6296654 Ward Oct 2001 B1
6299599 Pham et al. Oct 2001 B1
6305378 Lesh Oct 2001 B1
6306161 Ginsburg Oct 2001 B1
6312452 Dobak, III et al. Nov 2001 B1
6325818 Werneth Dec 2001 B1
6338727 Noda et al. Jan 2002 B1
6364899 Dobak, III Apr 2002 B1
6368304 Aliberto et al. Apr 2002 B1
6379378 Werneth et al. Apr 2002 B1
6383151 Diederich et al. May 2002 B1
6383180 Lalonde et al. May 2002 B1
6383210 Magers et al. May 2002 B1
6391224 Wowk May 2002 B1
6393320 Lasersohn et al. May 2002 B2
6405080 Lasersohn et al. Jun 2002 B1
6409747 Gobin et al. Jun 2002 B1
6416511 Lesh et al. Jul 2002 B1
6416533 Gobin et al. Jul 2002 B1
6419643 Shimada et al. Jul 2002 B1
6428563 Keller Aug 2002 B1
6432124 Worthen et al. Aug 2002 B1
6652515 Maguire et al. Nov 2003 B1
20010001830 Dobak, III et al. May 2001 A1
20010001831 Dobak, III et al. May 2001 A1
20010001832 Dobak, III et al. May 2001 A1
20010002442 Dobak, III May 2001 A1
20010005791 Ginsburg et al. Jun 2001 A1
20010007927 Koblish et al. Jul 2001 A1
20010007951 Dobak, III Jul 2001 A1
20010008975 Dobak, III et al. Jul 2001 A1
20010010011 Aliberto et al. Jul 2001 A1
20010011184 Dobak, III et al. Aug 2001 A1
20010011185 Dobak, III et al. Aug 2001 A1
20010014802 Tu Aug 2001 A1
20010016763 Lasheras et al. Aug 2001 A1
20010016764 Dobak, III Aug 2001 A1
20010021865 Dobak, III et al. Sep 2001 A1
20010021866 Dobak, III et al. Sep 2001 A1
20010027333 Schwartz Oct 2001 A1
20010029394 Dobak, III et al. Oct 2001 A1
20010031946 Walker et al. Oct 2001 A1
20010032003 Pecor Oct 2001 A1
20010032004 Werneth Oct 2001 A1
20010039440 Lasheras et al. Nov 2001 A1
20010041923 Dobak, III Nov 2001 A1
20010044644 Keller et al. Nov 2001 A1
20010047191 Lasersohn et al. Nov 2001 A1
20010047192 Lasersohn et al. Nov 2001 A1
20010047196 Ginsburg et al. Nov 2001 A1
20010049545 Lasersohn et al. Dec 2001 A1
20020002394 Dobak, III Jan 2002 A1
20020004675 Lasheras Jan 2002 A1
20020007179 Dobak, III et al. Jan 2002 A1
20020007202 Dobak, III et al. Jan 2002 A1
20020007203 Gilmartin et al. Jan 2002 A1
20020016621 Werneth et al. Feb 2002 A1
20020022823 Luo et al. Feb 2002 A1
20020026227 Philips Feb 2002 A1
20020029016 Pham et al. Mar 2002 A1
20020032430 Luo et al. Mar 2002 A1
20020032438 Lafontaine Mar 2002 A1
20020032474 Dobak, III et al. Mar 2002 A1
20020040717 Dobak, III Apr 2002 A1
20020045892 Kramer Apr 2002 A1
20020045925 Keller et al. Apr 2002 A1
20020049409 Noda et al. Apr 2002 A1
20020049410 Noda et al. Apr 2002 A1
20020049484 Werneth et al. Apr 2002 A1
20020066458 Aliberto et al. Jun 2002 A1
20020068964 Dobak, III Jun 2002 A1
20020077665 Kordis et al. Jun 2002 A1
20020077680 Noda Jun 2002 A1
20020082671 Magers et al. Jun 2002 A1
20020091378 Dobak, III et al. Jul 2002 A1
20020091429 Dobak, III et al. Jul 2002 A1
20020091430 Dobak, III et al. Jul 2002 A1
20020095200 Dobak, III et al. Jul 2002 A1
20020095201 Worthen et al. Jul 2002 A1
20020099364 LaLonde Jul 2002 A1
20020099427 Dobak, III Jul 2002 A1
20020103519 Dobak, III et al. Aug 2002 A1
20020111616 Dae et al. Aug 2002 A1
20020111657 Dae et al. Aug 2002 A1
20020115995 Lesh Aug 2002 A1
20020156469 Yon et al. Oct 2002 A1
Foreign Referenced Citations (112)
Number Date Country
730835 Aug 1997 AU
685559 Jan 1998 AU
743945 Aug 1998 AU
737433 Feb 1999 AU
739996 Aug 1999 AU
734506 Oct 1999 AU
2177982 Jun 1995 CA
1082382 Feb 1994 CN
0655225 May 1993 EP
0 664 990 Nov 1997 EP
1205167 May 2002 EP
2 447 406 Mar 1980 FR
806 029 Feb 1981 SU
WO9105528 May 1991 WO
WO9117788 Nov 1991 WO
WO9304727 Mar 1993 WO
WO9416760 Aug 1994 WO
WO9501814 Jan 1995 WO
WO9515115 Jun 1995 WO
WO9607448 Mar 1996 WO
WO9610367 Apr 1996 WO
WO9640347 Dec 1996 WO
WO9701374 Jan 1997 WO
WO9725011 Jul 1997 WO
WO9826831 Jun 1998 WO
WO9831312 Jul 1998 WO
WO9837822 Sep 1998 WO
WO9838934 Sep 1998 WO
WO9849957 Nov 1998 WO
WO 0004211 Jan 1999 WO
WO9900064 Jan 1999 WO
WO9902096 Jan 1999 WO
WO9927862 Jun 1999 WO
WO9937726 Jul 1999 WO
WO9948449 Sep 1999 WO
WO9944519 Oct 1999 WO
WO9952455 Oct 1999 WO
WO9956812 Nov 1999 WO
WO9966970 Dec 1999 WO
WO9966971 Dec 1999 WO
WO 0009054 Feb 2000 WO
WO 0010494 Mar 2000 WO
WO 0032126 Jun 2000 WO
WO 0038601 Jul 2000 WO
WO 0042931 Jul 2000 WO
WO 0042932 Jul 2000 WO
WO 0042933 Jul 2000 WO
WO 0047145 Aug 2000 WO
WO 0048670 Aug 2000 WO
WO 0048760 Aug 2000 WO
WO 0051511 Sep 2000 WO
WO 0051534 Sep 2000 WO
WO 0051683 Sep 2000 WO
WO 0053135 Sep 2000 WO
WO 0056237 Sep 2000 WO
WO 0057823 Oct 2000 WO
WO 0059390 Oct 2000 WO
WO 0062837 Oct 2000 WO
WO 0066053 Nov 2000 WO
WO 0067648 Nov 2000 WO
WO 0067656 Nov 2000 WO
WO 0067830 Nov 2000 WO
WO 0067832 Nov 2000 WO
WO 0072779 Dec 2000 WO
WO 0072787 Dec 2000 WO
WO 0076570 Dec 2000 WO
WO 0103606 Jan 2001 WO
WO 0108580 Feb 2001 WO
WO 0110323 Feb 2001 WO
WO 0110365 Feb 2001 WO
WO 0112061 Feb 2001 WO
WO 0112122 Feb 2001 WO
WO 0113809 Mar 2001 WO
WO 0113837 Mar 2001 WO
WO 0117471 Mar 2001 WO
WO 0119447 Mar 2001 WO
WO 0126590 Apr 2001 WO
WO 0130413 May 2001 WO
WO 0134225 May 2001 WO
WO 0137919 May 2001 WO
WO 0141664 Jun 2001 WO
WO 0141708 Jun 2001 WO
WO 0143661 Jun 2001 WO
WO 0149236 Jul 2001 WO
WO 0152781 Jul 2001 WO
WO 0154618 Aug 2001 WO
WO 0154764 Aug 2001 WO
WO 0156517 Aug 2001 WO
WO 0158397 Aug 2001 WO
WO 0164145 Sep 2001 WO
WO 0164146 Sep 2001 WO
WO 0166052 Sep 2001 WO
WO 0174276 Oct 2001 WO
WO 0176655 Oct 2001 WO
WO 0178580 Oct 2001 WO
WO 0187379 Nov 2001 WO
WO 0195840 Dec 2001 WO
WO 0207793 Jan 2002 WO
WO 0226175 Apr 2002 WO
WO 0226176 Apr 2002 WO
WO 0226285 Apr 2002 WO
WO 0226307 Apr 2002 WO
WO 0228300 Apr 2002 WO
WO 0236180 May 2002 WO
WO 0238091 May 2002 WO
WO 0243577 Jun 2002 WO
WO 0247577 Jun 2002 WO
WO 0247742 Jun 2002 WO
WO 02055129 Jul 2002 WO
WO 02056938 Jul 2002 WO
WO 02058606 Aug 2002 WO
WO 02060514 Aug 2002 WO
Related Publications (1)
Number Date Country
20020091378 A1 Jul 2002 US
Divisions (1)
Number Date Country
Parent 09516319 Mar 2000 US
Child 10039466 US
Continuation in Parts (2)
Number Date Country
Parent 09052545 Mar 1998 US
Child 09516319 US
Parent 09215038 Dec 1998 US
Child 09052545 US